Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alexion's Soliris To Treat EU Patients With NMOSD

Executive Summary

The market opportunity in the EU for Alexion’s Soliris has increased following European Commission approval of the additional indication, NMOSD. The EU indications for Bristol-Myers Squibb’s Empliciti have been extended to include use with pomalidomide and dexamethasone in a triplet combination for relapsed and refractory multiple myeloma.

You may also be interested in...



Merck KGaA Ties Up Chord To Advance Cladribine Rare Disease Programs

Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.

Genentech’s New NMOSD Drug Offers At-Home Treatment, Lower Cost

Enspryng (satralizumab) is the third FDA-approved drug but only at-home treatment for neuromyelitis optica spectrum disorder; significant percentage of patients are not being treated.

Roche Touts Safety Profile For NMOSD Drug Satralizumab

With Alexion's Soliris already approved, and Viela's inebilizumab within touching distance of an FDA green light, Roche is highlighting the safety profile of its investigational neuromyelitis optica spectrum disorder drug satralizumab.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel